Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EBT (2017 - 2025)

Protagonist Therapeutics' EBT history spans 9 years, with the latest figure at -$44.2 million for Q4 2025.

  • For Q4 2025, EBT fell 133.06% year-over-year to -$44.2 million; the TTM value through Dec 2025 reached -$129.8 million, down 146.45%, while the annual FY2025 figure was -$129.8 million, 146.45% down from the prior year.
  • EBT for Q4 2025 was -$44.2 million at Protagonist Therapeutics, down from -$39.3 million in the prior quarter.
  • Across five years, EBT topped out at $210.7 million in Q1 2024 and bottomed at -$44.2 million in Q4 2025.
  • The 5-year median for EBT is -$32.5 million (2024), against an average of -$2.7 million.
  • The largest annual shift saw EBT tumbled 335.45% in 2021 before it skyrocketed 724.66% in 2024.
  • A 5-year view of EBT shows it stood at $88.9 million in 2021, then tumbled by 138.55% to -$34.3 million in 2022, then skyrocketed by 186.13% to $29.5 million in 2023, then soared by 352.93% to $133.7 million in 2024, then tumbled by 133.06% to -$44.2 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's EBT are -$44.2 million (Q4 2025), -$39.3 million (Q3 2025), and -$34.6 million (Q2 2025).